Fact-check: Dr. Spencer Nadolsky on the top five GLP-1 side effects and what to do

What the video covers

Dr. Nadolsky takes the five effects his clinic sees most and, for each, gives the pattern, the prevention and the escalation. Nausea peaks early and fades; do not move up a dose until it is mild; avoid heavy fatty meals and split meals smaller; his clinic sometimes switches semaglutide to tirzepatide, and uses ondansetron or metoclopramide when needed. Constipation is constant rather than early; fluids, whole-food fibre, movement, then psyllium, then polyethylene glycol or magnesium citrate. Reflux follows slowed emptying; posture and smaller meals, then antacids, H2 blockers, proton pump inhibitors. Diarrhoea is usually self-limited. Fatigue a day or two after the injection is common, mechanism unknown, and not usually B12 deficiency.

What it gets right

The time course is the trial time course. Nausea in the STEP and SURMOUNT programs clustered around initiation and each dose increase and declined on maintenance; constipation persisted. His rule of not escalating until nausea has largely settled is consistent with both labels, which describe the schedule as a minimum interval and allow escalation to be delayed if a dose is not tolerated. The dietary advice, less fat, smaller and more frequent meals, hydration, fibre, is what the labels and dietitian guidance say, and he is right that fatty meals are the most reliable trigger.

He is careful about the medication steps: each is prefaced with "talk to your doctor", and he says he prefers to avoid adding drugs to treat the side effects of another drug. The fatigue section is honest about not knowing the mechanism and correctly says B12 supplementation is not indicated without a deficiency.

What it leaves out or overstates

The explanation for why tirzepatide is better tolerated, that the GIP component has anti-emetic action in the brain, is a hypothesis from animal work and is not established. The label rates do not show a large gap: nausea was 44 percent on Wegovy 2.4 mg and 25 to 29 percent across Zepbound doses, but the trials were not head-to-head on tolerability and the populations differed. Switching between molecules is a prescriber's decision with its own titration restart.

None of the drugs he names should be started on the strength of a video. Metoclopramide carries its own boxed warning about tardive dyskinesia with prolonged use; proton pump inhibitors have long-term considerations; laxative choice depends on the person. He says as much, but a summary of the video could lose those caveats, so we repeat them.

The video does not cover vomiting severe enough to cause dehydration, which is where the label's kidney warning lives, nor pancreatitis, gallbladder disease or the thyroid warning. It is a tolerability video, not a safety video, and should be paired with one.

Where to go next

The Stanford dietitian's webinar later in this playlist gives the trial percentages week by week. The emergency physician's video before this one covers the dehydration chain. For what to keep in a side-effect diary, FormBlends Tools and Templates has a printable. FormBlends' compounded products are described at formblends.com; compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with the pens whose label rates are quoted here.